^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    carboplatin

    i
    Other names: CBDCA, JM-8, JM8, NSC-241240, NSC-241240, NSC 241240, NSC-241-240
    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    2d
    Crystal structures, DNA interaction of natural anthraquinone compounds and dual apoptotic mechanisms in oral cancer CAL-27 cells. (PubMed, Biophys Chem)
    Among them, rhein exhibited significant anti-proliferative activity, superior to carboplatin, with an IC₅₀ value of 72.4 ± 3.7 μM against CAL-27 cells...Moreover, rhein not only activates the mitochondrial-mediated apoptosis signaling pathway (Bax/Bcl-2/cytochrome C/cleaved caspase-3) but also highly activates the expression level of the DNA damage protein γ-H2AX. This study provides new insights into the development of natural anthraquinone compounds as promising candidates for oral cancer therapies.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
    |
    carboplatin
    2d
    FIERCE: Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer (clinicaltrials.gov)
    P1, N=45, Active, not recruiting, University of Oklahoma | Trial completion date: Sep 2026 --> Jun 2027 | Trial primary completion date: Jul 2026 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel
    2d
    Primary Hepatoid Adenocarcinoma of the Lung With Signet Ring Cell Differentiation and Widespread Osseous Metastases: A Case Report. (PubMed, Respirol Case Rep)
    The patient received 3 cycles of gemcitabine plus carboplatin but experienced rapid clinical deterioration. This case underscores that HAL may mimic nonresolving pneumonia and that normal AFP does not exclude the diagnosis; early biopsy and a targeted immunohistochemical panel are essential for timely recognition of this lethal entity.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • AFP (Alpha-fetoprotein) • NKX2-1 (NK2 Homeobox 1) • CDX2 (Caudal Type Homeobox 2) • TP63 (Tumor protein 63)
    |
    carboplatin • gemcitabine
    3d
    TARMAC: MicroRNA Profiles in Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=42, Recruiting, University College Hospital, Ibadan | Trial completion date: Aug 2023 --> Aug 2030 | Trial primary completion date: Mar 2023 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • epirubicin
    3d
    M23-385: Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=288, Active, not recruiting, AbbVie | Trial completion date: Jun 2026 --> Nov 2027 | Trial primary completion date: Jun 2026 --> Nov 2027
    Trial completion date • Trial primary completion date • Adverse events • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • SEZ6 (Seizure Related 6 Homolog)
    |
    EGFR mutation • IDH wild-type
    |
    cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
    3d
    Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Washington University School of Medicine | Trial completion date: Dec 2034 --> Mar 2035 | Initiation date: Mar 2026 --> Jun 2026 | Trial primary completion date: Jan 2030 --> Apr 2030
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Hiltonol (poly-ICLC)
    3d
    HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (clinicaltrials.gov)
    P1, N=31, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed | Trial completion date: Jul 2026 --> Feb 2026
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    carboplatin • docetaxel • Perjeta (pertuzumab)
    3d
    Malignant transformation of a testosterone-secreting ovarian steroid cell tumor: a case report. (PubMed, Gynecol Oncol Rep)
    Despite adjuvant carboplatin, paclitaxel, and bevacizumab followed by maintenance therapy, she developed platinum-resistant progression with peritoneal and nodal disease and is currently receiving additional systemic therapy with poor response. This case highlights the potential for malignant transformation in benign-appearing SCT-NOS and underscores the importance of counseling patients on the rare risk of recurrence and the need for novel therapeutic strategies in recurrent disease. Integration of clinical, pathologic, and molecular data may improve risk stratification and management of this rare tumor.
    Journal
    |
    STK11 (Serine/threonine kinase 11) • LZTR1 (Leucine Zipper Like Transcription Regulator 1)
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel
    4d
    NRG-BR003: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=782, Active, not recruiting, NRG Oncology | Trial primary completion date: Oct 2026 --> Dec 2025
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide
    4d
    Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment (clinicaltrials.gov)
    P2, N=66, Recruiting, Guangdong Association of Clinical Trials | N=36 --> 66
    Enrollment change
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    carboplatin • etoposide IV • Hetronifly (serplulimab)
    4d
    NeoTHERa: Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer (clinicaltrials.gov)
    P2, N=100, Recruiting, University of Kansas Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive
    |
    carboplatin • docetaxel • Perjeta (pertuzumab)
    4d
    Leptomeningeal metastatic disease responding to carboplatin, pemetrexed, and amivantamab after progression to osimertinib in EGFR exon 21 L858R-Mutated non-small cell lung cancer: Two case reports. (PubMed, Respir Med Case Rep)
    To our knowledge, this is the first report to demonstrate the efficacy of carboplatin, pemetrexed, and amivantamab against LMD progression after osimertinib therapy, suggesting that this regimen may be a therapeutic option for patients with LMD, including those with symptomatic disease. Nevertheless, further studies are warranted to confirm efficacy in this population.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R
    |
    Tagrisso (osimertinib) • carboplatin • pemetrexed